Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis

Trial end date:
Target enrollment:
Participant gender:
To evaluate the no-inferiority of the ketoconazole20mg/g and betamethasone dipropionate 0.64 mg/g association (Candicort®) cream versus clotrimazole 10mg and dexamethasone acetate 0.443 mg/g association (Baycuten N®) cream, general relief of signs and symptoms (erythema, maceration, peeling, blistering / papules / pustules, itching and burning / stinging) 06 (± 1) days after onset treatment.
Phase 3
Accepts Healthy Volunteers?
Lead Sponsor:
Ache Laboratorios Farmaceuticos S.A.
BB 1101
Betamethasone benzoate
Betamethasone sodium phosphate
Betamethasone Valerate
Dexamethasone 21-phosphate
Dexamethasone acetate
Inclusion Criteria:

- Ability to understand and consent to participate in this clinical research, expressed
by signing the Informed Consent Form (ICF);

- Participants with moderate or severe clinical diagnosis of superficial mycoses caused
by Candida ssp or following fungal /dermatophytosis infections: inflammatory tinea
corporis inflammatory (except face), inflammatory tinea cruris and inflammatory tinea
pedis, with confirmation through direct mycological examination. In moderate or severe
superficial mycosis that present at least moderate erythema and itching signs and
slight peeling according to the evaluation by the four-point category scale (0=absent,
1-mild, 2-moderate, 3-severe);

Exclusion Criteria:

- Any observational finding (clinical/ physical evaluation) that is interpreted by the
investigator as a risk to the research participant's participation in the clinical

- Known hypersensitivity to the drug components used during the study;

- Use of prohibited drugs and treatment prohibited in the last 90 days;

- Immune impairment, according to investigator assessment;

- Vulvovaginal candidiasis diagnostics, balanopreputial, nail, chronic mucocutaneous or

- Diagnosis of chickenpox, rosacea, herpes simplex or zoster, skin tuberculosis or skin
syphilis, systemic fungal infection;

- Participants who, though they have studied diagnosis of fungal infections requiring
systemic treatment according to the severity of injury and according to the opinion of
the investigator;

- Participants that have skin lesions with clinical signs of bacterial infection;

- Participants who, according to investigator assessment, require systemic antibiotic

- Participants that are in any treatment , in the opinion of the investigator, may
affect the results of the study;

- Participants diagnosed with HIV;

- Participants diagnosed with Diabetes Mellitus;

- Participants with a history of smallpox vaccine reaction;

- Women in gestation period or who are breastfeeding;

- Female participants who are in the reproductive age and do not agree to use acceptable
methods of contraception (oral contraceptives, injectable contraceptives, intrauterine
device (IUD), hormonal implants, barrier methods, hormonal patch and tubal ligation);
except surgically sterile (bilateral oophorectomy or hysterectomy), the menopausal for
at least one year and participants who declare to perform sexual practices on a not to
reproductive way;

- Participant who participated in clinical in the last twelve months, unless the
investigator considers that there may be direct benefit to thereof;

- Participant has some kinship of second degree or bond with employees or employees of
Sponsor and Research Center.